Heron Therapeutics HRTX · Forecast & Analysis
The view on Heron Therapeutics (HRTX) is bullish, driven by the definitive agreement to sell substantially all assets for cash, CorMedix shares and possible earn-outs. With no technical signals available, the call rests on this deal alone.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Outlook for Heron Therapeutics
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- Unanimously board-approved sale of substantially all assets for $145 million cash plus CorMedix stock.
- Up to $55 million in earn-outs tied to 2028 ZYNRELEF net sales plus a 5% royalty above sales thresholds.
- Holders of about 22% of shares, including Rubric, have agreed to vote in favor, supporting deal completion.
- Proceeds will repay the Hercules credit facility, and Heron remains listed with a significant CorMedix stake.
What argues against it
- Closing is expected only in Q1 2027, pending stockholder approval, antitrust clearance and other conditions.
- The CorMedix share portion is fixed in number, so its value to holders depends on CorMedix's share price.
- No premium to Heron's current share price is stated in the deal terms.
What would change the picture
- A shareholder vote in favor, or regulatory clearance, would move the deal toward its expected Q1 2027 closing.
- A fall in CorMedix's share price would shrink the stock portion of the consideration received.
- US inflation reports due shortly set the broader market backdrop but carry no fixed direction for the stock.
Coming up
- US: Jobless claims
- US: EIA Crude Oil Stocks Change
- US: Producer prices · expected 0.4%, previous 0.7%
Economic data for HRTX
Full calendarRecently released
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%
- TodayUSDCPI●●●Forecast 338.683Previous 336.298
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%
Coming up
- November 12, 2026USDInitial Jobless Claims●●●in 1 day
- November 12, 2026USDEIA Crude Oil Stocks Change●●●in 2 days
- November 13, 2026USDCore PPI m/m●●●Forecast 0.4%Previous 0.7%in 2 days
- November 13, 2026USDPPI m/m●●●Forecast 0.4%Previous 1.3%in 2 days
- November 17, 2026USDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 6 days
- November 17, 2026USDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 6 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about HRTX
Frequently asked questions about Heron Therapeutics
What has Heron Therapeutics actually agreed to?
A definitive agreement, approved unanimously by the board, to sell substantially all assets for $145 million in cash plus CorMedix stock valued at about $77.6 million, with additional earn-outs and a 5% royalty tied to ZYNRELEF sales above agreed thresholds.
What could still prevent the deal from completing?
The sale needs approval from Heron's stockholders, expiration of the antitrust waiting period and other customary conditions, with closing expected only in the first quarter of 2027. Holders of about 22% of shares, including Rubric, have already committed to vote in favor, which supports completion.
Is there a premium to the current share price in the terms?
No premium to Heron's current share price is stated. What holders ultimately receive also depends on the fixed number of CorMedix shares in the package, which are worth whatever CorMedix trades at — cited at $5.32 as of November 6, 2026.
📝 Overview Generated automatically
HRTX has been the subject of 1 signals across 1 articles in the last 365 days. Sentiment skews Bullish (100%).
Breakdown: 1 bullish, 0 bearish, 0 neutral.
Most-cited catalysts: Definitive asset purchase agreement announced November 9, 2026 with upfront consideration valued at approximately $222.6 million (1×), Up to $55 million in earn-out payments tied to 2028 ZYNRELEF net sales plus a 5% royalty above thresholds (1×). Most-cited risk factors: Deal still requires Heron stockholder approval, HSR antitrust waiting-period expiration and other customary conditions, with closing expected only in Q1 2027 (1×), Stock portion is 14,583,333 CorMedix shares fixed in number, so its value to Heron holders depends on CorMedix's share price of $5.32 as of November 6, 2026 (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.